Ask about this productRelated genes to: MDM2 antibody
- Gene:
- MDM2 NIH gene
- Name:
- MDM2 proto-oncogene
- Previous symbol:
- -
- Synonyms:
- HDM2, MGC5370
- Chromosome:
- 12q15
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-10
- Date modifiied:
- 2017-12-01
Related products to: MDM2 antibody
Related articles to: MDM2 antibody
- Ovarian cancer (OC) is the second lethal gynecological malignancy, with chemoresistance being a major therapeutic challenge. Interestingly, although malignant ascites is generally associated with poor prognosis, tumor-suppressing factors have been identified in ascitic fluid. This study aims to identify chemotherapy-sensitizing peptides in OC ascites and elucidate its underlying mechanisms. - Source: PubMed
Publication date: 2026/10/01
Geng ZheWang ZhenlongPan XinxingXia ChengjieWang HongmeiWang XuanXu HanziXu JuanJia Xuemei - Treatment options for hepatocellular carcinoma (HCC) remain unsatisfactory, and JAK2 continues to attract interest as a point of pharmacological intervention in this malignancy. The present work asked whether Neoruscogenin, a spirostanol sapogenin, and its predicted human metabolites can engage that node. Intersecting predicted compound targets with HCC-associated genes returned 97 shared proteins. Degree-based ranking placed IL2, SRC, STAT3, MTOR, PIK3CB, MAPK1, JAK2, MDM2, KIT and MAPK14 at the center of the resulting interaction network, and functional enrichment pointed toward cancer-related, MAPK, PI3K-Akt, apoptotic and immune-associated signaling. Four biotransformation products retaining the steroidal core were carried forward. Across ten prioritized receptors, the parent compound scored best against JAK2 (PDB 5AEP, -10.48 kcal/mol), among the metabolites, the 3-O-glucuronide BTM00003 came within 0.17 kcal/mol of it (-10.31 kcal/mol), and both exceeded the reference inhibitor QUP (-8.87 kcal/mol). All three complexes survived 200 ns of unrestrained dynamics, but the routes to stability differed: free energy landscape, principal component and cross-correlation analyses described a narrow, dynamically restrained basin for QUP, whereas Neoruscogenin and BTM00003 stayed bound while exploring wider conformational space. MMGBSA returned favorable binding free energies for all three, with QUP most negative. Predicted ADMET combined near-complete intestinal absorption for Neoruscogenin with poor aqueous solubility and a hepatotoxicity alert, and DFT descriptors described a hard, electronically stable scaffold. Neoruscogenin and its glucuronide therefore merit experimental follow-up in HCC as starting points rather than as optimized candidates. - Source: PubMed
Publication date: 2026/09/29
Tu Tan QuangNguyen Quan HuuNguyen Hung DucChu Mau Hoang - The p53 protein is a central tumour suppressor regulating numerous genes involved in cell cycle control, DNA repair, and apoptosis. Mutations in p53 occur in over half of all cancers, disrupting these regulatory pathways and enhancing tumour progression. Many cell lines, including MCF-7 breast cancer cells, exhibit oscillatory p53 and MDM2 activity, a phenomenon linked to radiosensitivity and the cellular response to ionizing radiation. - Source: PubMed
Publication date: 2026/10/01
Danilova IrinaKlementová JanaJarošová ŠárkaKundrát PavelZíková MartinaDavídková Marie - Uveal melanoma (UM) is a rare but aggressive intraocular malignancy originating in the uvea (choroid, iris, and ciliary body). Despite primary treatment, 50% of UM patients develop metastases to the liver, lungs, bones, and skin. Topotecan, a topoisomerase I inhibitor, and SP141, an MDM2 inhibitor, have been studied in cancers, including retinoblastoma. This study explores a combined approach with these drugs in the 92-1 UM cell line. - Source: PubMed
Publication date: 2026/09/24
Thomas AnjuAddi Utkarsh RWu AudriannaKozak KaleighCollery Ross FJoshi AmitRamasubramanian AparnaChaurasia Shyam S - Well-differentiated liposarcoma (WDLPS) is a low-grade malignancy characterized by an indolent clinical course and a strong tendency for local recurrence. Unlike other sarcoma subtypes, pure WDLPS has a very low metastatic potential. However, in the course of the disease, dedifferentiation may occur and is associated with a substantially higher risk of metastases and mortality. Surgery remains the cornerstone of treatment for both primary and recurrent abdominal WDLPS, when a complete resection is possible. The role of systemic therapy in WDLPS is less clearly defined. Conventional cytotoxic chemotherapy generally has limited activity in pure WDLPS, and most clinical trials have included both WDLPS with dedifferentiated liposarcoma (DDLPS) or other liposarcoma subtypes, making the data for pure WDLPS difficult to interpret. Therefore, in clinical practice, we consider systemic treatment for patients with unresectable, symptomatic disease and in cases of repeated recurrences in which further local treatment is not possible. For selected patients with indolent and asymptomatic disease, active surveillance remains an appropriate strategy. The recent development of treatments directed against molecular alterations in WDLPS, namely CDK4 and MDM2 amplifications, have opened up a new era in the systemic treatment of this disease. Among these, anti-CDK4 agent palbociclib has shown the most mature clinical evidence to date, including recent results of overall survival data. MDM2 inhibition and combinations targeting both CDK4 and MDM2 represent promising areas which are currently under investigation. Due to the rarity of WDLPS and the lack of evidence from prospective studies, enrollment in clinical trials should be prioritized whenever possible. - Source: PubMed
Publication date: 2026/09/30
Boulouta AnnaDigklia AntoniaStergioula AnastasiaKyriazoglou Anastasios